Adelines Lab

InCube Labs is a multi-disciplinary life sciences lab based in San Jose, CA, focused on developing and commercializing breakthrough innovations in the field of healthcare. With a portfolio of 24 companies and 15 successful exits, InCube Labs aims to create new standards of care in medicine by focusing on the convergence of drugs and devices, as well as developing novel therapies for chronic diseases. Their innovative solutions have the potential to improve the lives of millions of patients. Rani, one of the companies founded within InCube Labs, is dedicated to making oral biologics a reality by developing a platform capable of delivering a wide range of biologics for the treatment of various chronic diseases. SacraMed, another portfolio company, focuses on the development of a neuromodulation system for the treatment of overactive bladder (OAB), a common bladder disorder. Fe3 Medical is working on a breakthrough transdermal therapy for iron deficiency anemia, while Neurolink is developing a novel therapy for epilepsy. Theracle is dedicated to developing an implantable drug-device combination therapy for brain cancer, bypassing the blood-brain barrier to provide targeted treatment with minimal adverse effects.Generated from the website

Glow Glass Studio, located in Oakland's arts district, is the creative hub of artist and designer Alexander Abajian, who has been exploring the medium of glass since 2010. The studio is renowned for its ability to produce large-scale glass sculptures and high-output blown or pressed glass, solidifying its reputation as a premier destination for glass fabrication. With nearly 30 years of experience, Abajian merges his mastery of hot glass manipulation with innovative design, resulting in stunning lighting pieces and custom glass projects. The skilled team at Glow Glass Studio has collaborated with notable clients, specializing in everything from architectural sculpture to public art installations and restoration work. Generated from the website

Caribou Biosciences, Inc., based in Berkeley, CA, is a clinical-stage biopharmaceutical company dedicated to developing innovative genome-edited allogeneic cell therapies aimed at treating severe human diseases. Utilizing next-generation CRISPR genome-editing technology, the company focuses on creating off-the-shelf CAR-T cell therapies to enable rapid and broad patient access in the fight against hematologic malignancies. Caribou is recognized as a leader in the CRISPR field, employing its proprietary chRDNA technology to enhance the efficacy of its cell therapies through strategies such as checkpoint disruption and immune cloaking. With a commitment to advancing transformative medical treatments, the company aims to significantly improve patient outcomes in challenging health conditions. Generated from the website